Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Aethlon Medical reveals therapeutic device strategy for breast cancer

Aethlon Medical : 21 September, 2011  (Company News)
Aethlon Medical is introduicng HER2osome, a novel medical device strategy to inhibit the progression of HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein.

Breast cancer represents the most common form of invasive cancer in women. HER2+ breast cancer accounts for approximately 25 percent of new breast cancer diagnosis.


The goal of HER2osome therapy is to simultaneously reduce the circulatory presence of HER2 protein and breast cancer exosomes, which have increasingly become recognized as playing pivotal role in the development and progression of breast cancer.  Researchers report that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer. 


As an adjunct therapeutic candidate, HER2osome offers to address an unmet medical need and enhance the benefit of Herceptin and standard of care chemotherapies without adding drug toxicity or interaction risks.

 

To support the pre-clinical and clinical advancement of HER2osome, Aethlon has submitted a funding proposal entitled: 'An Innovative Device Strategy to Eliminate HER2 Breast Cancer Progression' to the Breast Cancer Research Program (BCRP) offered through the Assistant Secretary of Defense for Health Affairs, Defense Health Program. The BCRP was established in fiscal year 1992 (FY92) to support innovative research focused on eradicating breast cancer.  Appropriations for the BCRP from FY92 through FY10 totaled over $2.5 billion. The FY11 appropriation is $150 million.  Principal investigators underlying the Aethlon BCRP funding proposal are Dr CS Chen, Chief, Division of Hematology and Oncology and Medical Director of the Loma Linda Cancer Center, and Dr Douglas Taylor, Professor, Department of Obstetrics and Gynecology at University of Louisville School of Medicine.


The evolution of HER2osome therapy is based upon an adaptable dialysis-like affinity platform technology known as the Aethlon ADAPT system.  Therapies evolved from the Aethlon ADAPT system target the selective clearance of harmful agents from the entire blood volume within clinically relevant time frames and without the loss of essential blood components. Thus, overcoming the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity agents in the outer-capillary space of plasma filtration membrane technology as a means to provide rapid real-time clearance of corresponding targets.  In the case of HER2osome, the immobilization of a HER2 antibody and an exosome targeted affinity agent provides a mechanism to clear both targets from the circulatory system of HER2+ breast cancer patients.  Like all ADAPT derived therapi es, HER2osome will operate dialysate free, will not require replacement fluids, and can be utilized on dialysis machines or CRRT systems already located in hospitals and clinics worldwide.


Aethlon has previously applied its ADAPT system through a proposal chosen for funding through a DOD contract award under DARPA-BAA-11-30 entitled 'Dialysis-Like Therapeutics'.  The proposed programme, which is pending completion of a contracting phase, would support the development of a therapeutic device that reduces the incidence of sepsis in wounded warfighters through the selective clearance of circulating septic precursors.

 

The genesis of the ADAPT system is the Hemopurifier, a device that immobilises a single lectin affinity agent to provide broad-spectrum capabilities against viral pathogens and immunosuppressive proteins. Human studies have demonstrated the Hemopurifier to be safe and provide average viral load reductions of greater than 50 percnet during four-hour treatment periods in both hepatitis-C (HCV) and HIV infected individuals without the administration of antiviral drugs. 


The device is currently the subject of a human clinical study to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy.  An investigational device exemption (IDE) to initiate clinical studies in the United States has been submitted to The Food and Drug Administration (FDA).


In vitro studies recently documented that the Hemopurifier also captures exosomes underlying cancer, including colorectal, lymphoma, melanoma, ovarian, and breast cancer. On August 24th, Aethlon expanded its exosome research programs through a collaborative agreement with the Sarcoma Oncology Center (SOC), based in Santa Monica, California, USA. The SOC collaboration will study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients. 


The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma.  Exosomes released by cancers have emerged to become an important therapeutic target in cancer care, as they are implicated in cancer survival, growth, and metastasis.  Researchers have also identified that cancer-released exosomes may assist tumours in evading the response of the immune system. 

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo